Renaissance Technologies
VRPX

Renaissance Technologies’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Renaissance Technologies’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-122
Closed -$10K – 4204
2023
Q4 		$10K Sell
122
-162
-57% -$24.3K ﹤0.01% 3645
2023
Q3 		$57K Sell
284
-73
-20% -$16.1K ﹤0.01% 3383
2023
Q2 		$97K Sell
357
-24
-6% -$4.97K ﹤0.01% 3484
2023
Q1 		$75K Sell
381
-4
-1% -$893 ﹤0.01% 3575
2022
Q4 		$60K Sell
385
-248
-39% -$56.5K ﹤0.01% 3764
2022
Q3 		$188K Sell
633
-180
-22% -$64.8K ﹤0.01% 3406
2022
Q2 		$341K Buy
813
+187
+30% +$76.7K ﹤0.01% 3383
2022
Q1 		$348K Buy
+626
New +$365K ﹤0.01% 3402

Other funds holding VRPX

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SRCM
Signature Resources Capital Management Newport Beach, California $254M AUM 26.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Renaissance Technologies's VRPX Position: Q1 2024 in Review

Renaissance Technologies sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q1 2024, closing a stake of 122 shares — an estimated $10K sold.

Renaissance Technologies first reported a position in VRPX in Q1 2022 and held it in 8 quarters. The position peaked at $348K in Q1 2022. 3 funds tracked by Wall St. Rank hold VRPX as of Q1 2024.

  • Renaissance Technologies reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Renaissance Technologies sold 122 Virpax Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $10K.
  • Renaissance Technologies first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
  • Renaissance Technologies's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $348K in Q1 2022.
  • 3 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.